Edgestream Partners L.P. acquired a new stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 124,063 shares of the biopharmaceutical company’s stock, valued at approximately $1,865,000. Edgestream Partners L.P. owned approximately 0.13% of Ultragenyx Pharmaceutical as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently made changes to their positions in RARE. Allworth Financial LP grew its stake in shares of Ultragenyx Pharmaceutical by 18.9% in the third quarter. Allworth Financial LP now owns 5,588 shares of the biopharmaceutical company’s stock worth $84,000 after purchasing an additional 889 shares during the last quarter. Versant Capital Management Inc lifted its holdings in shares of Ultragenyx Pharmaceutical by 662.9% in the second quarter. Versant Capital Management Inc now owns 1,152 shares of the biopharmaceutical company’s stock valued at $38,000 after purchasing an additional 1,001 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of Ultragenyx Pharmaceutical by 149.5% during the second quarter. GAMMA Investing LLC now owns 1,919 shares of the biopharmaceutical company’s stock valued at $64,000 after buying an additional 1,150 shares during the last quarter. Sterling Capital Management LLC grew its holdings in Ultragenyx Pharmaceutical by 102.4% during the third quarter. Sterling Capital Management LLC now owns 2,475 shares of the biopharmaceutical company’s stock worth $37,000 after buying an additional 1,252 shares in the last quarter. Finally, Quantbot Technologies LP bought a new stake in Ultragenyx Pharmaceutical during the second quarter worth $48,000. 97.67% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
Several brokerages have weighed in on RARE. Barclays dropped their price objective on Ultragenyx Pharmaceutical from $35.00 to $32.00 and set an “overweight” rating on the stock in a research note on Thursday, November 5th. HC Wainwright dropped their price target on shares of Ultragenyx Pharmaceutical from $50.00 to $25.00 and set a “buy” rating on the stock in a research report on Thursday, September 3rd. Royal Bank Of Canada cut shares of Ultragenyx Pharmaceutical from a “moderate buy” rating to a “hold” rating in a report on Thursday, September 3rd. Morgan Stanley upped their price objective on shares of Ultragenyx Pharmaceutical from $20.00 to $22.00 and gave the stock an “equal weight” rating in a research report on Wednesday, November 4th. Finally, Robert W. Baird cut shares of Ultragenyx Pharmaceutical from an “outperform” rating to a “neutral” rating and dropped their target price for the stock from $40.00 to $16.00 in a research report on Thursday, September 3rd. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $29.79.
Insider Activity
In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 7,066 shares of the stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $15.27, for a total transaction of $107,897.82. Following the sale, the chief financial officer owned 89,229 shares in the company, valued at $1,362,526.83. This represents a 7.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 8,510 shares of company stock worth $127,561 in the last quarter. Corporate insiders own 5.20% of the company’s stock.
Ultragenyx Pharmaceutical Stock Performance
Shares of RARE opened at $16.48 on Friday. Ultragenyx Pharmaceutical Inc. has a fifty-two week low of $12.73 and a fifty-two week high of $39.89. The business has a 50-day moving average of $15.51 and a 200 day moving average of $22.33. The firm has a market cap of $1.68 billion, a P/E ratio of -3.18 and a beta of 0.37.
Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report) last released its quarterly earnings data on Tuesday, November 3rd. The biopharmaceutical company reported ($1.16) EPS for the quarter, missing the consensus estimate of ($1.10) by ($0.06). The business had revenue of $173.00 million for the quarter, compared to analyst estimates of $182.49 million. During the same quarter in the previous year, the business posted ($1.81) earnings per share. The firm’s revenue was up 8.2% on a year-over-year basis. As a group, research analysts predict that Ultragenyx Pharmaceutical Inc. will post -3.21 earnings per share for the current fiscal year.
Ultragenyx Pharmaceutical Profile
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare genetic diseases. Founded in 2010 and headquartered in Novato, California, the company works on therapies for conditions with limited treatment options, including enzyme deficiencies and metabolic disorders. Its marketed products include Crysvita (burosumab), used to treat certain forms of X-linked hypophosphatemia and tumor-induced osteomalacia; Mepsevii (vestronidase alfa), for mucopolysaccharidosis VII; and Dojolvi (triheptanoin), for long-chain fatty acid oxidation disorders.
Featured Stories
- Five stocks we like better than Ultragenyx Pharmaceutical
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
